Traduction de «moody’s rated the group » (Néerlandais → Français) :

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities and Standard & Poor’s had a rating of AA- and A-1+, for long-term and short-term maturities, respectively. Fitch had a long-term rating of AA and a short-term rating of F1+.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities, and Standard & Poor’s had ratings of AA- for long-term and A-1+ for short-term maturities. Fitch had a long-term rating of AA and a short-term rating of F1+.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

Moody’s rated the Group as Aa2 for long-term maturities and P-1 for short-term maturities and Standard & Poor’s had a rating of AA- and A-1+, for long-term and shortterm maturities, respectively.
Moody’s a noté le Groupe Aa2 pour les maturités longues et P-1 pour les maturités courtes, Standard & Poor’s respectivement AA- et A-1+ et Fitch respectivement AA et F1+.

The long-term credit rating for the company continues to be AA (Standard & Poor’s AA-; Moody’s Aa2).
La note de crédit à long terme de Novartis demeure AA (Standard & Poor’s: AA-; Moody’s: Aa2).

It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, dividedd by the overall rate in the population. In this chapter, we highlighted the indicators for which we observed a relative risk (RR) as large as 1.2 (or 0.83 when the gradient was reverse).
It is computed as the difference between the overall rate in the population and the rate in the more advantaged group, divided by the overall rate in the population.

Taxes The tax rate (taxes as a percentage of pre-tax income) was 15.2% in the first half of 2009 compared to 14.0% in the year-ago period based on a reassessment of the Group’s anticipated full-year tax rate.
Impôts Le taux d’imposition (exprimé en pourcentage du résultat avant impôts) s’est élevé à 15,2% au premier semestre 2009, en comparaison de 14,0% au premier semestre 2008, par suite d’une réévaluation du taux d’imposition attendu pour l’exercice complet du Groupe.

The Group’s net sales are expected to grow at a midsingle-digit rate in 2009, while Pharmaceuticals net sales are expected to grow at a mid- to high-single-digit rate, both in local currencies.
Le chiffre d’affaires net du Groupe devrait croître, en 2009, à un taux à un chiffre dans la partie moyenne de la fourchette, tandis que celui de Pharmaceuticals devrait enregistrer une progression à un taux à un chiffre dans la partie moyenne à haute de la fourchette en monnaies locales.

2010 outlook Novartis is building momentum in 2010 and reaffirms expectations for Group net sales to grow at a mid-single-digit percentage rate in constant currencies (excluding Alcon) and for improvement in the Group’s operating income margin in 2010, driven by the business expansion and ongoing productivity gains.
Perspectives 2010 Novartis prend un nouvel essor en 2010 et réaffirme ses attentes concernant le chiffre d’affaires net du Groupe qui devrait croître à un taux à un chiffre dans le milieu de la fourchette, à taux de change constants (hors Alcon), et la marge opérationnelle du Groupe qui devrait s'améliorer sous l'effet de l'expansion des activités et des gains continus de productivité.

Breast cancer (age group 40 - 49): observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)
Breast cancer (age group 40 - 49) : observed and estimated specific mortality rate / 100 000 women per year in Flanders (Belgium) (1999-2006)

The incidence rate in unscreened women can be observed, as in the control group of a randomised trial, or it can be estimated on the basis of the incidence before screening or in other populations not offered screening 10 .
The incidence rate in unscreened women can be observed, as in the control group of a randomised trial, or it can be estimated on the basis of the incidence before screening or in other populations not offered screening 11 .